Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease

Sridhar, Vinay; Gaud, Ram; Bajaj, Amrita; Wairkar, Sarika

doi:10.1016/j.nano.2018.08.004

Cited by 92 publications

(29 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of Parkinson’s disease through the administration of polymeric nanocarriers has also been studied. Thus, administering chitosan nanoparticles through the intranasal route for the delivery of selegiline [110] and pramipexole [111] increases the brain targeting efficiency and the amount of drug reaching the brain by decreasing the pre-systemic metabolism. Moreover, the in vitro and in vivo studies on the delivery of apolipoprotein E and α-mangostin by using phosphatidic acid-conjugated liposomes [112] and transferrin-modified liposomes [113], respectively, confirmed the potential for an enhanced BBB permeation and efficient drug delivery.…”

Section: Nanomedicine In Central Nervous System Disordersmentioning

confidence: 99%

Neuronanomedicine: An Up-to-Date Overview

et al. 2019

View full text Add to dashboard Cite

The field of neuronanomedicine has recently emerged as the bridge between neurological sciences and nanotechnology. The possibilities of this novel perspective are promising for the diagnosis and treatment strategies of severe central nervous system disorders. Therefore, the development of nano-vehicles capable of permeating the blood–brain barrier (BBB) and reaching the brain parenchyma may lead to breakthrough therapies that could improve life expectancy and quality of the patients diagnosed with brain disorders. The aim of this review is to summarize the recently developed organic, inorganic, and biological nanocarriers that could be used for the delivery of imaging and therapeutic agents to the brain, as well as the latest studies on the use of nanomaterials in brain cancer, neurodegenerative diseases, and stroke. Additionally, the main challenges and limitations associated with the use of these nanocarriers are briefly presented.

show abstract

Section: Nanomedicine In Central Nervous System Disordersmentioning

confidence: 99%

Neuronanomedicine: An Up-to-Date Overview

et al. 2019

View full text Add to dashboard Cite

show abstract

“…For the treatment of Parkinson’s disease, which is associated with motor features, such as rest tremor, bradykinesia, rigidity and postural instability, olfactory dysfunction, cognitive impairment, psychiatric symptoms, and autonomic dysfunction [59], various types of nanoparticles have been studied. Some of these studies reported ex vivo of chitosan nanoparticles for the delivery of Selegiline, a well-known anti-Parkinson agent [60], and Pramipexole [61], a non-ergot based dopamine that effectively counters Parkinson’s diseases progression [62]. Additionally, the use of cerium oxide nanoparticles, which protect neurons against reactive oxygen species-induced damage, has resulted in the improvement of motor dysfunctions and decreased apoptosis [63].…”

Section: The Use Of Nanoparticles For the Diagnosis And Treatment mentioning

confidence: 99%

Impact of Nanoparticles on Brain Health: An Up to Date Overview

Teleanu

Chircov

Grumezescu

et al. 2018

JCM

169

View full text Add to dashboard Cite

Nanoparticles are zero-dimensional nanomaterials and, based on their nature, they can be categorized into organic, inorganic, and composites nanoparticles. Due to their unique physical and chemical properties, nanoparticles are extensively used in a variety of fields, including medicine, pharmaceutics, and food industry. Although they have the potential to improve the diagnosis and treatment of brain diseases, it is fundamentally important to develop standardized toxicological studies, which can prevent the induction of neurotoxic effects. The focus of this review is to emphasize both the beneficial and negative effects of nanoparticles on brain health.

show abstract

“…Likewise, metformin-loaded polydopamine NPs promote anti-inflammatory, antiapoptotic, and antioxidative properties associated with the proteolytic degradation of phosphorylated serine 129 of α-synuclein protein induced by targeting a histone-lysine N-methyltransferase enzyme known as the enhancer of zeste homolog 2 (Sardoiwala et al, 2020). Other NPs and nanodrugs that have been reported to have significant potential in the treatment of PD by regulating oxidative stress and inflammation including vitamin E-loaded naringenin nanoemulsions (Gaba et al, 2019), selegiline CS NPs (Sridhar et al, 2018), borneol and lactoferrin comodified NPs (Tang et al, 2019), resveratrol NPs (Palle and Neerati, 2018), and Cerium NPs (Hegazy et al, 2017). In summary, NPs and nanodrugs have great potential in treatment of PD because of their role in the regulation of inflammation, oxidative stress, apoptosis, α-synuclein activities, and the downstream effects in motor and non-motor dysfunctions.…”

Section: Pdmentioning

confidence: 99%

The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

Ngowi

Wang

Qian

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Brain is by far the most complex organ in the body. It is involved in the regulation of cognitive, behavioral, and emotional activities. The organ is also a target for many diseases and disorders ranging from injuries to cancers and neurodegenerative diseases. Brain diseases are the main causes of disability and one of the leading causes of deaths. Several drugs that have shown potential in improving brain structure and functioning in animal models face many challenges including the delivery, specificity, and toxicity. For many years, researchers have been facing challenge of developing drugs that can cross the physical (blood–brain barrier), electrical, and chemical barriers of the brain and target the desired region with few adverse events. In recent years, nanotechnology emerged as an important technique for modifying and manipulating different objects at the molecular level to obtain desired features. The technique has proven to be useful in diagnosis as well as treatments of brain diseases and disorders by facilitating the delivery of drugs and improving their efficacy. As the subject is still hot, and new research findings are emerging, it is clear that nanotechnology could upgrade health care systems by providing easy and highly efficient diagnostic and treatment methods. In this review, we will focus on the application of nanotechnology in the diagnosis and treatment of brain diseases and disorders by illuminating the potential of nanoparticles.

show abstract

Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease

Cited by 92 publications

References 34 publications

Neuronanomedicine: An Up-to-Date Overview

Neuronanomedicine: An Up-to-Date Overview

Impact of Nanoparticles on Brain Health: An Up to Date Overview

The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

Contact Info

Product

Resources

About